DOXORUBICINE ARROW 2 mg/ml

DRUG4 trials

Sponsors

Unicancer, Institut Curie, Hospices Civils De Lyon, Institut Paoli Calmettes

Conditions

Breast cancerFIGO stage I (2018 classification)Localizedneoplastic pleural effusionresectedtriple‑negative breast canceruterine leiomyosarcoma

Phase 1

"FAP-IT" 68Ga-FAPI-46 PET/CT for predicting histological response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer

RecruitingCTIS2023-507860-37-00

Institut CurieBreast cancer

Start: 2024-10-14Target: 300Updated: 2025-11-10

Phase 2

L-UteCIN : Interest of adjuvant chemotherapy in patients with CINSARC high-risk localized resected uterine leiomyosarcoma

RecruitingCTIS2023-506350-21-00

UnicancerLocalized, resected, FIGO stage I (2018 classification) +1

Start: 2025-01-06Target: 198Updated: 2025-03-25

PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy

Not yet recruitingCTIS2025-523482-23-00

Hospices Civils De Lyonneoplastic pleural effusion

Target: 20Updated: 2026-07-16

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

Not yet recruitingCTIS2025-525040-18-00

Institut Paoli Calmettestriple‑negative breast cancer

Target: 84Updated: 2026-07-24